About us
IMIWN is a division of J R Biomedical Ltd., a UK-based medical diagnostics company that develops and manufactures in-vitro diagnostics for use in hospital laboratories.
Established in 2005, the company is ISO 13485:2016 certified for the development, assembly, and distribution of in-vitro diagnostic (IVD) medical devices to hospital laboratories and research institutions.
Recently, in collaboration with Cardiff University, the company developed and commercialised a novel, rapid lateral-flow assay targeting Soluble Toll-Like Receptor 2 (sTLR2), an ultra-early immune response marker for inflammation and sepsis.
Commercial out-licensing and distribution opportunities are available for the:
- sTLR2 RAPID - a 10 minute, lateral flow assay for use with serum, plasma and whole blood
- Proprietary panel of anti-human sTLR2 hybridomas and monoclonal antibodies
- Anti-sTLR2 antibody pairs, and;
- Anti-sTLR2 polyclonal antibodies
Currently, the sTLR2 RAPID test is available as an MHRA registered, UKCA certified IVD in Great Britain, and for research use only (RUO) assay elsewhere. The sTLR2 RAPID test offers new insights into early immune system activation, opening immediate commercial opportunities in clinical trial stratification, therapeutic monitoring, and fast-track IVD co-development.